Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.

Novavax (NasdaqGS:NVAX) recently amended its collaboration agreement with Takeda, enhancing its revenue potential through a new upfront payment structure and future royalties. These developments, ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) ...

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell. The company’s earnings beat estimates by 32% in the last reported ...

(RTTNews) - Novavax, Inc. (NVAX ... the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (NYSE:TAK). The terms of the amended agreement for the development, ...

The U.S. FDA is asking Novavax (NASDAQ:NVAX) to conduct an additional randomized, controlled study of its COVID-19 vaccine ...

Novavax (NVAX) closed the most recent trading ... At the same time, the Dow added 1.39%, and the tech-heavy Nasdaq gained 1.51%. Coming into today, shares of the vaccine maker had gained 14. ...

Shares of Novavax (NASDAQ:NVAX) rose on Wednesday after the company revealed U.S. FDA's request for additional clinical data ...

empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For Novavax, the consensus EPS estimate for the quarter has ...